EMA Authorised: Spikevax (previously COVID-19 Vaccine Moderna) (single-stranded, 5’-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2) — Moderna Biotech Spain, S.L.

View source ↗

Summary

The EMA has authorised Spikevax (Moderna) for use in the EU; it is an mRNA vaccine encoding the SARS-CoV-2 spike protein for COVID-19.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• COVID-19 Disease

Drugs mentioned

• Spikevax (mRNA-1273)

Snippet

Status: Authorised. Therapeutic area: COVID-19 virus infection. MAH: Moderna Biotech Spain, S.L.. Decision date: 28/07/2026